The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response

AIDS

Volumn 13, Issue 9, 1999, Pages 1099-1107

  Haubrich, Richard H ^a,b   Little, Susan J ^a   Currier, Judith S ^d   Forthal, Donald N ^c   Kemper, Carol A ^e   Beall, Gildon N ^f   Johnson, Debra ^d   Dubé, Michael P ^d   Hwang, Jimmy Y ^a,b   McCutchan, J Allen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Adherence; Antiretroviral therapies; HIV RNA; Therapeutic response

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; ALCOHOL ABUSE; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DRUG ABUSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FORECASTING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0032808202     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199906180-00014     Document Type: Article

References (33)

1. 1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
2. 2. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998, 338:853-860.
3. 3. Reggy A, Wong T, Chiasson M, et al. Protease inhibitors and declining AIDS deaths in New York City. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998. [Late Breaker 7].
4. 4. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996, 335:1081-1090.
5. 5. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
6. 6. Haubrich R, Lalezari J, Follansbee SE, et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998, 3:33-42.
7. 7. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
8. 8. Staszewski S, Hill AM, Bartlett J, et al. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997, 11:477-483.
9. 9. Costagliola D. Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French university hospitals. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998. [Abstract 182].
10. 10. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
11. 11. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995, 333:1528-1533.
12. 12. Markowitz M, Saag M, Powderly WC, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
13. 13. Steigbigel RT, Berry P, Mellors J, et al. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating doses. Third Conference on Retrovirus and Opportunistic Infections. Washington, DC, January-February 1996. [Abstract 146].
14. 14. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996, 276:1955-1956.
15. 15. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
16. 16. Tisdale M, Myers RE, Maschera B, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agent Chemother 1995, 39:1704-1710.
17. 17. Markowitz M, Ho DD. Protease inhibitors-mechanisms and clinical aspects. In Antiviral Drug Resistance. Edited by Ricman D, Chichester, NY: Wiley; 1996:261-279.
18. 3. Fifth Conference on Retrovirus and Opportunistic Infections Chicago, February 1998. [Abstract 513].
19. 19. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996, 8:261-269.
20. 20. Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997, 102:164-170.
21. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September-October, 1997 [Abstract 1-180].
22. 22. Eldred I, Wu A, Chaisson RE, Moore RD. Adherence to antiretroviral therapy in HIV disease. Fourth Conference on Retrovirus and Opportunistic Infections. Washington, DC, January 1997. [Abstract 257].
23. 23. Besch CL, Morse E, Simon P, Hodges J, Franchino B. Preliminary results of a compliance study within CPCRA 007 combination nucleoside study (NuCombo). Fourth Conference on Retrovirus and Opportunistic Infections. Washington, DC, January 1997. [Abstract 254].
24. 24. Bangsberg DR, Zolopa AR, Charlebois E, et al. HIV-infected homeless and marginally housed (H/M) patients adhere to and receive early virology benefit from protease inhibitors (PI). Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998. [Abstract 152].
25. 25. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Int Med 1994, 154:1121-1127.
26. 26. Steiner JF. Provider assessments of compliance with zidovudine. Arch Int Med 1995, 155:135-336.
27. 27. Knobel H, Serrano C, Hernández P, Pavesi M, Díez A. Acceptance of, compliance with and tolerance to antiretroviral treatment in patients with human immunodeficiency virus infection. Ann Med Int 1997, 14:445-449.
28. 28. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995, 7:439-447.
29. 29. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Education and Prevention 1996, 8:58-71.
30. 30. Samel JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992, 92:495-502.
31. 31. Geletko SM, Segarra M, Mayor KH, et al. Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrob Agent Chemother 1996, 40:1338-1341.
32. 32. Tebas P, Royal M, Fichtenbaum C, et al. Relationship between adherence to HAART and disease state. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998. (Abstract 149).
33. 33. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998. [Abstract 151].